Functional Neurological Disorder
Stroke 51:1629-1635, Popkirov, S., et al, 2020
Systemic Review of Malpractice Litigation in the Diagnosis and Treatment of Acute Stroke
Stroke 50:2858-2864, Haslett, J.J.,et al, 2019
Streamlined Hyeracute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression is Stroke Mimic
Stroke 47:1012-1017, Goyal, M.S.,et al, 2016
Safety of Intravenous Thrombolysis in Stroke Mimics
Stroke 46:1281-1287, Tsivgoulis, G.,et al, 2015
Safety of Thrombolysis in Patients with Acute Ischemic Stroke and Cerebral Cavernous Malformations
Stroke 45:1846-1848, Erdur, H.,et al, 2014
Safety of Thrombolysis in Stroke Mimics
Stroke 44:1080-1084, Zinkstok, S.M.,et al, 2013
Negative Diffusion-Weighted Imaging After Intravenous Tissue-Type Plasminogen Activator is Rare and Unlikely to Indicate Averted Infarction
Stroke 44-1629-1634, Freeman, J.,et al, 2013
Safety and Outcomes of Intravenous Thrombolysis in Stroke Mimics
Stroke 42:1771-1774, Tsivgoulis, G.,et al, 2011
Safety of tPA in Stroke Mimics and Neuroimaging-Negative Cerebral Ischemia
Neurol 74:1340-1345, 1336, Chernyshev,O.Y., et al, 2010
Neuroimaging in Acute Posterior Cerebral Artery Infarction
The Neurologist 14:170-180, Finelli,P.F., 2008
Vertebrobasilar Disease
NEJM 352:2618-2626, Savitz,S.I.&Caplan,L.R., 2005
Stroke Mimicry: Four Cases Eligible for Tissue Plasminogen Activator
The Neurologist 6:220-223, Kirshner, H.S., 2000
Cranial CT Interpret in Acute Stroke, Physician Accuracy in Determ Elig for Thrombolytic Therapy
JAMA 279:1293-1297, 13071998., Schriger,D.L.,et al, 1998